Treatment of Patients With BRCA Mutated Pancreatic Cancer: The Clinical Perspective

Download slides from Clinical Care Options (CCO) in which experts provide multidisciplinary insights on the use of checkpoint inhibitors for HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Released: April 30, 2021

In this slideset from Clinical Care Options (CCO), experts discuss their thoughts on the use of regorafenib and TAS-102 for colorectal cancer (CRC).

Joleen Hubbard, MD John L. Marshall, MD Released: April 29, 2021

Steven Waguespack, MD, on hypothyroidism after immune checkpoint inhibitors, MIBG treatment, or mitotane, and the mechanism of hyperthyroidism in cancer survivors from Clinical Care Options (CCO)

Steven G. Waguespack, MD Released: April 26, 2021

Laurie Cohen, MD, on when and how to retest for GH deficiency, how soon to start GH replacement in cancer survivors from Clinical Care Options (CCO)

Laurie E. Cohen, MD Released: April 22, 2021